February 12, 2018 / 10:15 PM / 7 months ago

BRIEF-Vertex Pharma Says Established Wholesale Acquisition Cost Of $292,000 For SYMDEKO In U.S. On Annual Basis

Feb 12 (Reuters) - Vertex Pharmaceuticals Inc:

* VERTEX PHARMA - HAVE ESTABLISHED WHOLESALE ACQUISITION COST FOR SYMDEKO IN UNITED STATES OF $292,000 ON ANNUAL BASIS ($22,400 PER 28-DAY PACK)

* VERTEX PHARMA SAYS ANTICIPATE FY 2018 TOTAL CF NET PRODUCT REVENUE OF $2.65 BILLION TO $2.80 BILLION FROM KALYDECO, ORKAMBI AND SYMDEKO - SEC FILING

* VERTEX PHARMACEUTICALS -REITERATING ‍COMBINED GAAP RESEARCH AND DEVELOPMENT, SALES, GENERAL, ADMINISTRATIVE EXPENSES IN 2018 TO BE IN RANGE OF $1.80 TO $1.95 BILLION

* VERTEX PHARMA- ‍ REITERATING COMBINED NON-GAAP RESEARCH AND DEVELOPMENT AND SALES, GENERAL, AND ADMINISTRATIVE EXPENSES WILL BE IN RANGE OF $1.50 BILLION TO $1.55 BILLION IN 2018​ Source text: (bit.ly/2BTkdmr) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below